<code id='88A343F02F'></code><style id='88A343F02F'></style>
    • <acronym id='88A343F02F'></acronym>
      <center id='88A343F02F'><center id='88A343F02F'><tfoot id='88A343F02F'></tfoot></center><abbr id='88A343F02F'><dir id='88A343F02F'><tfoot id='88A343F02F'></tfoot><noframes id='88A343F02F'>

    • <optgroup id='88A343F02F'><strike id='88A343F02F'><sup id='88A343F02F'></sup></strike><code id='88A343F02F'></code></optgroup>
        1. <b id='88A343F02F'><label id='88A343F02F'><select id='88A343F02F'><dt id='88A343F02F'><span id='88A343F02F'></span></dt></select></label></b><u id='88A343F02F'></u>
          <i id='88A343F02F'><strike id='88A343F02F'><tt id='88A343F02F'><pre id='88A343F02F'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:Wikipedia    Page View:98814

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In